Stryker Corporation $SYK Holdings Cut by Stillwater Wealth Management Group

Stillwater Wealth Management Group cut its position in shares of Stryker Corporation (NYSE:SYK) by 84.2% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,190 shares of the medical technology company’s stock after selling 6,357 shares during the period. Stillwater Wealth Management Group’s holdings in Stryker were worth $328,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. State Street Corp grew its stake in shares of Stryker by 1.2% in the 2nd quarter. State Street Corp now owns 15,532,565 shares of the medical technology company’s stock valued at $4,903,772,000 after buying an additional 183,400 shares during the period. Wellington Management Group LLP raised its position in shares of Stryker by 0.6% during the 2nd quarter. Wellington Management Group LLP now owns 8,167,185 shares of the medical technology company’s stock valued at $2,571,357,000 after buying an additional 45,478 shares during the period. Bank of America Corp DE purchased a new stake in shares of Stryker during the 2nd quarter valued at approximately $1,404,284,000. Royal Bank of Canada raised its position in shares of Stryker by 6.5% during the 1st quarter. Royal Bank of Canada now owns 3,273,232 shares of the medical technology company’s stock valued at $1,075,552,000 after buying an additional 199,863 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Stryker by 21.8% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,689,376 shares of the medical technology company’s stock valued at $846,723,000 after acquiring an additional 481,175 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Stryker

In other news, insider Dylan Crotty sold 441 shares of the stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $328.61, for a total transaction of $144,917.01. Following the sale, the insider owned 6,102 shares of the company’s stock, valued at approximately $2,005,178.22. This represents a 6.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Debra King sold 826 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the transaction, the insider directly owned 6,210 shares of the company’s stock, valued at approximately $2,088,423. The trade was a 11.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 351,267 shares of company stock valued at $118,197,701 in the last three months. 4.60% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts recently weighed in on the company. Piper Sandler lowered their price objective on Stryker from $420.00 to $390.00 and set an “overweight” rating for the company in a research report on Friday, July 31st. Wolfe Research cut Stryker from an “outperform” rating to a “peer perform” rating in a research note on Thursday, August 13th. UBS Group assumed coverage on Stryker in a research report on Tuesday, July 28th. They issued a “buy” rating and a $400.00 target price on the stock. JPMorgan Chase & Co. decreased their price target on Stryker from $400.00 to $350.00 and set an “overweight” rating on the stock in a research note on Friday, July 31st. Finally, Wells Fargo & Company cut their price objective on Stryker from $418.00 to $348.00 and set an “overweight” rating for the company in a research report on Wednesday, September 9th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $369.00.

Stryker Trading Down 2.3%

Shares of SYK traded down $7.07 during midday trading on Wednesday, hitting $297.33. 1,193,869 shares of the stock were exchanged, compared to its average volume of 2,450,214. Stryker Corporation has a 52-week low of $267.00 and a 52-week high of $392.55. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. The stock has a fifty day simple moving average of $297.53 and a 200 day simple moving average of $312.37. The firm has a market cap of $114.05 billion, a P/E ratio of 30.77, a P/E/G ratio of 1.92 and a beta of 0.78.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%. The firm had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. During the same quarter in the previous year, the business earned $3.13 EPS. The company’s quarterly revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, research analysts anticipate that Stryker Corporation will post 14.93 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 1.2%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s payout ratio is currently 36.48%.

Stryker Company Profile

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.